 SAN DIEGO, Aug. 02, 2022 GLOBE NEWSWIRE -- BioAtla, Inc. Nasdaq: BCAB, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic CAB antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, August 9, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide business highlights. 